Mylan has announced the initiation of two phased-3 trials for a biosimilar Sanofi's drug Lantus, or the generic version Glargine. The trials were initiated in August 2014 and Mylan is expecting to complete it possibly by June 2016.
This is important for Biocon because the company has a partnership with Mylan for Glargine. Glargine is a biosimilar drug which has been studied in terms of long acting insulin for curing diabetes.
The size of the drug is expected to be around USD 3-4 billion globally. Biocon developed this drug which was later out-licensed to Mylan to develop it further.
According to Mylan, after Glargine gets commercialised, Biocon will begin getting royalties on this particular drug.
Biocon already has a version of this in the Indian markets at this point in time but the latest move will result in a possible launch in developed markets. So it would be a significant upside for Biocon in the longer term.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
